[A case of secondary myelodysplastic syndrome following chemotherapy for lung cancer].
A case of secondary myelodysplastic syndrome (MDS) following chemotherapy for lung cancer is reported. A 78-year-old man, with a smoking history of 20 cigarettes/day for 55 years, was incidentally, diagnosed as having stage IV squamous cell carcinoma of the lung in 1987 during admission for transurethral resection of bladder cancer. He received combination chemotherapy of mitomycin C, vincristin, and cisplatin for his lung cancer between July and September 1988. His clinical course remained almost stable until October 1989, when his blood count showed severe anemia and thrombocytopenia. He was diagnosed as having secondary MDS induced by cytotoxic agents used for the treatment of lung cancer, based on the dysplastic findings of precursor cells in the bone marrow and the chromosome abnormality of 51XY, +8, +9, +21, 3p-, 5q-, +2mar. He died of infection with the progression of MDS in March 1990.
Uemura
M
M
First Department of Internal Medicine, Kyoto Prefecture University of Medicine, Japan.
Kasamatsu
Y
Y
Sawada
M
M
Takemura
S
S
Sugino
S
S
Kondou
M
M
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D002294:Carcinoma, Squamous Cell / Q000150:complications* / Q000235:genetics; D002295:Carcinoma, Transitional Cell / Q000150:complications; D006801:Humans; D008175:Lung Neoplasms / Q000150:complications* / Q000235:genetics; D008297:Male; D016685:Mitomycin / Q000009:adverse effects; D009190:Myelodysplastic Syndromes / Q000209:etiology* / Q000235:genetics; D009378:Neoplasms, Multiple Primary; D011374:Progesterone / Q000009:adverse effects; D001749:Urinary Bladder Neoplasms / Q000150:complications; D014747:Vinblastine / Q000009:adverse effects
D011374:Progesterone; D016685:Mitomycin; D014747:Vinblastine